Protext Mobility Announces Acquisition of Cannabis
Post# of 3448
(Total Views: 361)
Posted On: 11/27/2017 12:29:38 AM
Protext Mobility Announces Acquisition of Cannabis Biosciences Inc.
Source: http://www.marketwired.com/press-release/prot...205404.htm
Here is part of the article:
Protext Mobility, Inc. (OTC PINK: TXTM) ("Protext" or "the Company"
, a biotech company engaged in the development of pharmaceutical applications for the highly bioavailable Phytofare® catechin complex, today announced its acquisition of Cannabis Biosciences Inc. from Plandaí Biotechnology Inc. Under the terms of the transaction, Protext acquired 100% of the capital stock of Cannabis Biosciences in exchange for 50 million shares of its common stock. Plandaí has indicated that the shares acquired from Protext will be distributed to Plandaí shareholders as a stock dividend. Protext will now operate its two wholly owned subsidiaries as independent operating businesses. The new business unit, Cannabis Biosciences, will focus on developing cannabis extracts under legal government licenses and permits which the Company is currently pursuing. Plandaí Biotechnology South Africa, the other business unit, is engaged in the research and clinical testing of "bioceutical" products -- all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. The Company has the exclusive worldwide license to develop pharmaceutical applications and products using the Phytofare® catechin complex produced from green tea grown on the Senteeko estate.
Cannabis Biosciences was formed and incorporated by Plandaí Biotechnology in 2013 to legally develop non-psychoactive medicines from live cannabis plant. Using Plandaí's proprietary processing and extraction technology, the company intends to commence investigations in conjunction with independent researchers to develop and validate a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-
found in live cannabis plant. The hypothesis is that the resultant extract will have similar, superior bioavailability of other Phytofare® extracts with the added benefit of being non-psychoactive. Several third-party investigations have shown that the precursor acid forms THC-A and THC-B in live cannabis leaf are inherently non-psychoactive and that the process of drying and heating the leaf metabolizes these acid forms into THC, a chemical that triggers the euphoria sought after by recreational users. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential.
Source: http://www.marketwired.com/press-release/prot...205404.htm
Here is part of the article:
Protext Mobility, Inc. (OTC PINK: TXTM) ("Protext" or "the Company"
, a biotech company engaged in the development of pharmaceutical applications for the highly bioavailable Phytofare® catechin complex, today announced its acquisition of Cannabis Biosciences Inc. from Plandaí Biotechnology Inc. Under the terms of the transaction, Protext acquired 100% of the capital stock of Cannabis Biosciences in exchange for 50 million shares of its common stock. Plandaí has indicated that the shares acquired from Protext will be distributed to Plandaí shareholders as a stock dividend. Protext will now operate its two wholly owned subsidiaries as independent operating businesses. The new business unit, Cannabis Biosciences, will focus on developing cannabis extracts under legal government licenses and permits which the Company is currently pursuing. Plandaí Biotechnology South Africa, the other business unit, is engaged in the research and clinical testing of "bioceutical" products -- all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. The Company has the exclusive worldwide license to develop pharmaceutical applications and products using the Phytofare® catechin complex produced from green tea grown on the Senteeko estate. Cannabis Biosciences was formed and incorporated by Plandaí Biotechnology in 2013 to legally develop non-psychoactive medicines from live cannabis plant. Using Plandaí's proprietary processing and extraction technology, the company intends to commence investigations in conjunction with independent researchers to develop and validate a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-
found in live cannabis plant. The hypothesis is that the resultant extract will have similar, superior bioavailability of other Phytofare® extracts with the added benefit of being non-psychoactive. Several third-party investigations have shown that the precursor acid forms THC-A and THC-B in live cannabis leaf are inherently non-psychoactive and that the process of drying and heating the leaf metabolizes these acid forms into THC, a chemical that triggers the euphoria sought after by recreational users. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential.
(0)
(0)
Marijuana Stocks Millionaire Club
Quote:
Timing is everything.